Procure a new WD-XRF for Color Certification Analysis.

The FDA Office of Acquisition and Grant Services is seeking to procure a new wavelength-dispersive X-ray fluorescence (WD-XRF) spectrometer to sustain the mission-critical Color Certification Program under 21 CFR Part 74. This instrument is essential for high-throughput analysis of elemental impurities in certifiable color additives, enabling accurate certification or rejection decisions, supporting regulatory sample analysis with unknown elemental compositions, and advancing research into improved analytical methods. The acquisition is not subject to any set-aside provisions and falls under NAICS code 334516, targeting advanced analytical instrumentation specifically designed for precise elemental detection in complex matrices. The solicitation, designated OC-2026-134665, was posted on July 27, 2026, with proposals due by August 7, 2026. Performance of the contract will occur at College Park, Maryland, while the contracting office is located in Rockville, Maryland. Bidders must provide equipment with guaranteed service support, including timely maintenance and repair capabilities to ensure uninterrupted operational continuity. Primary point of contact for inquiries is David Seid, reachable via phone or email through the FDA’s HHS domain. The contract is being procured through a combined solicitation process, and all responses must meet the technical and service requirements to support the FDA’s regulatory and scientific obligations.